JONATHAN FRYER, MD
Radiology at Saint Clair St, Chicago, IL
License number
Illinois 036090859
Category
Radiology
Type
Surgery
Address
Address
675 N Saint Clair St, Chicago, IL 60611
Phone
(312) 695-8900
(312) 695-9194 (Fax)
(312) 695-9194 (Fax)
Personal information
See more information about JONATHAN FRYER at radaris.comName
Address
Phone
34 Robinwood Dr, Rushville, IL 62681
39 Robinwood Dr, Rushville, IL 62681
605 Patty Dr, Maryville, IL 62062
190 Skyline View Dr, Collinsville, IL 62234
908 Wells Ave, Caseyville, IL 62232
Organization information
See more information about JONATHAN FRYER at bizstanding.comJonathan Fryer MD
676 N Saint Clair St, Lbby, Chicago, IL 60611
Categories:
Clinics & Medical Centers, Cosmetic & Reconstructive Surgeons
Site:
Phone:
(312) 695-8900 (Phone)
Products:
Military & Veteran's Services
Payment options:
All Major Cards Accepted, American Express, MasterCard, ...
Professional information
See more information about JONATHAN FRYER at trustoria.com
Dr. Jonathan P Fryer, Chicago IL - MD (Doctor of Medicine)
Dr. Jonathan P Fryer, Chicago IL - MD (Doctor of Medicine)
Specialties:
General Surgery
Address:
Kovlar Organ Transplant Center
676 N Saint Clair St SUITE 100, Chicago 60611
(312) 695-8900 (Phone)
676 N Saint Clair St SUITE 100, Chicago 60611
(312) 695-8900 (Phone)
Procedures:
Bone Marrow Biopsy, Colectomy, Dressing and/or Debridement of Wound, Infection, or Burn (incl. Negative Pressure Wound Therapy), Enterostomy (Laparoscopic or Open), Excision, Shaving, or Destruction of Skin and Subcutaneous Tissue (incl. Mohs Micrographic Surgery), Tissue Transfer, Gallbladder Removal, Laparoscopic, Hepatectomy, Incisional/Ventral Hernia Repair, Open, Inguinal Hernia Repair, Open, Intestinal Transplant (incl. Enterectomy), Liver Transplant, Lymph Node Biopsy or Excision, Pancreatectomy (incl. Pancreas Transplant & Whipple Procedure), Peripheral Artery Catheterization, Port Placements or Replacements, Renal Transplant and Nephrectomy, Thoracentesis, Thromboendarterectomy or Excision of Infected Graft, Tracheal Surgery
Conditions:
Biliary Atresia, Cholecystitis and Gallstones, Colorectal Cancer, Crohn's Disease (Regional Enteritis), Diaphragmatic/Hiatal Hernia, Esophageal Varices, Gallbladder & Biliary Tract Cancer, Hemorrhoids, Hyperparathyroidism, Incisional Hernia, Inguinal Hernia, Intestinal Obstruction, Lipomas, Liver Cancer, Peripheral Arterial Embolism and Thrombosis, Peripheral Vascular Disease (PAD, PVD), Thyroid Cancer, Ulcerative Colitis, Umbilical Hernia, Ventral Hernia
Certifications:
General Surgery, 1992
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Kovlar Organ Transplant Center
676 N Saint Clair St SUITE 100, Chicago 60611
Northwestern Memorial Hospital
251 East Huron St, Chicago 60611
676 N Saint Clair St SUITE 100, Chicago 60611
Northwestern Memorial Hospital
251 East Huron St, Chicago 60611
Education:
Medical School
University Of Manitoba Faculty Of Medicine
Graduated: 1985
Manitoba Affil Hosps
Graduated: 1986
University Manitoba/Affil Tchg Hosps
Graduated: 1991
University Minn Hospital
Graduated: 1994
University Western Ontario/U Hospital
Graduated: 1995
University Of Manitoba Faculty Of Medicine
Graduated: 1985
Manitoba Affil Hosps
Graduated: 1986
University Manitoba/Affil Tchg Hosps
Graduated: 1991
University Minn Hospital
Graduated: 1994
University Western Ontario/U Hospital
Graduated: 1995
Jonathan P Fryer, Chicago IL
Jonathan P Fryer, Chicago IL
Specialties:
Surgeon
Address:
675 N Saint Clair St, Chicago, IL 60611
676 N Saint Clair St, Chicago, IL 60611
676 N Saint Clair St, Chicago, IL 60611
Board certifications:
American Board of Surgery Certification in Surgery
Method And Material For Inhibiting Complement
Method And Material For Inhibiting Complement
US Patent:
6232293, May 15, 2001
Filed:
Sep 20, 1999
Appl. No.:
9/398238
Inventors:
Byron E. Anderson - Morton Grove IL
Jonathan P. Fryer - Chicago IL
Jonathan P. Fryer - Chicago IL
International Classification:
C07K 506
US Classification:
514 19
Abstract:
The invention provides a method of inhibiting complement in a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan-tryptophan. The invention further provides a method of prolonging the survival of tissue transplanted into a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan-tryptophan. The invention also provides a method of treating an inflammatory response in a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan-tryptophan. Finally, the invention provides a pharmaceutical composition comprising a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan-tryptophan in a pharmaceutically-acceptable vehicle.
Synthetic Peptide And Its Uses
Synthetic Peptide And Its Uses
US Patent:
5932483, Aug 3, 1999
Filed:
Apr 5, 1996
Appl. No.:
8/628383
Inventors:
Michael A. Baumann - Grayslake IL
Byron E. Anderson - Morton Grove IL
Jonathan P. Fryer - Chicago IL
Byron E. Anderson - Morton Grove IL
Jonathan P. Fryer - Chicago IL
Assignee:
Northwestern University - Evanston IL
International Classification:
G01N 33564
US Classification:
436507
Abstract:
The invention provides a fragment of C1q which is characterized in that a plurality of such fragments selectively binds immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. The invention also provides a synthetic peptide comprising the sequence:
Leu Glu Gln Gly Glu Asn Val Phe Leu Gln Ala Thr 1 5 10 �SEQ ID NO 2!
or variants thereof capable of binding immunoglobulin. Like the C1q fragment, a plurality of the peptides can selectively bind immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. As a result of this property, the fragments and peptides are well-adapted for removing immune complexes and aggregated immunoglobulins from fluids containing monomeric immunoglobulin, and for detecting or quantitating immune complexes in such fluids. The invention also provides a binding material for removing immune complexes or aggregated immunoglobulins from a fluid. The binding material comprises plural binding peptides, the peptides being characterized in that a plurality of them selectively binds immune complexes and aggregated immunoglobulins in the presence of monomeric immunoglobulin.
Method And Material For Inhibiting Complement
Method And Material For Inhibiting Complement
US Patent:
5977076, Nov 2, 1999
Filed:
Apr 14, 1998
Appl. No.:
9/060393
Inventors:
Byron E. Anderson - Morton Grove IL
Jonathan P. Fryer - Chicago IL
Jonathan P. Fryer - Chicago IL
International Classification:
A61K 3805
US Classification:
514 19
Abstract:
The invention provides a method of inhibiting complement in a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan--tryptophan. The invention further provides a method of prolonging the survival of tissue transplanted into a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan--tryptophan. The invention also provides a method of treating an inflammatory response in a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan--tryptophan. Finally, the invention provides a pharmaceutical composition comprising a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan--tryptophan in a pharmaceutically-acceptable vehicle.